Association of Clinical Features and Hematological Laboratoriesbetween Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia

Authors

Wulyo Rajabto, Divisi Hemotologi-Onkologi Medik, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/RSUPN dr.Cipto Mangunkusumo, Jakarta
A. Harryanto, Divisi Hemotologi-Onkologi Medik, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/RSUPN dr.
Hilman Tadjoedin, Unit Epidemiologi, Departemen Ilmu Penyakit Dalam, Fakultas Kedokter
Kuntjoro Harimurti, Unit Epidemiologi, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia/RS dr. Cipto Mangunkusumo, Jakarta

Abstract

Introduction. Patients with chronic phase Chronic Myeloid Leukemia (CML) at Hematology-Medical Oncology Clinic Department of Internal Medicine dr. Cipto Mangunkusumo National Hospital who haveperformed cytogenetic and RTPCR BCR-ABL examination showed: Ph (+)/BCR-ABL (+) CML and other type of Ph/BCR-ABL CML. This study aims to identify the clinical features and hematological laboratories of chronic phase CML, the proportion of Ph (+)/BCR-ABL (+) CML, and association of clinical features and hematological laboratories between Ph (+)/BCR-ABL (+) CML and other type of Ph/ BCR-ABL CML. Methods. This is a cross-sectional study. The samples were taken by consecutive method. We used Chi-square test and logistic regression analysis. Association between variables considered significant when p value <0.05. Results. There were 80 subjects with chronic phase CML. Mean of age was: 39.4 (standard deviation 13.1) years. The comparison of clinical features and hematological laboratories between Ph (+)/BCR-ABL (+) CML and other type of Ph/ 12 | Jurnal Penyakit Dalam Indonesia | Vol. 5, No. 1 | Maret 2018 Wulyo Rajabto, A. Harryanto, Hilman Tadjoedin, Kuntjoro Harimurti BCR-ABL CML were: Symptomatic 80.6% : 100%; splenomegaly 82% : 92.3%; median of Hb 10,3 g/dL : 10,3 g/dL; median of white blood cell 124.620 : 127.050; median of thrombocyte 455.000 : 487.000. Bivariate and multivariate analysis showed no significant association of clinical features and hematological laboratories between Ph (+)/BCR-ABL (+) CML and other type of Ph/BCR-ABL CML. Conclusion. There was no significant association of clinical features and hematological laboratories between Ph (+)/BCRABL (+) CML and other type of Ph/BCR-ABL CML.

References

1. Buyukasik Y, Haznedaroglu IC, Ilhan O. Chronic myeloid leukemia: Practical issues in diagnosis, treatment, and follow up. Int J Hematol Oncol. 2010;20(2 Suppl 1):1-12. 2. Pavlovsky C, Kantarjian H, Cortes JE. First line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol. 2009;84(5):287-293. 3. Erter JW, Garzon R. Current approach to treating chronic myeloid leukemia. Hematology. 2009;4:1-12 16 | Jurnal Penyakit Dalam Indonesia | Vol. 5, No. 1 | Maret 2018 Wulyo Rajabto, A. Harryanto, Hilman Tadjoedin, Kuntjoro Harimurti 4. Appleby M, Burke E, Curran TE, Neary E. Chronic myeloid leukemia: molecular abnormalities and treatment option. TSMJ; 2007;6:45- 51. 5. Goldman J. Chronic myeloid leukaemia. In: Provan D, ed. ABC of clinical haematology 2nd ed. London: BMJ Books; 2003. p.19-22. 6. Hofmann VS, Baccarani M, Hasford J, et al. THE EUTOS populationbased registry: incidence and clinical characteristics of 2904 CML patients in 20 european countries. Leukemia. 2015;29(6):1336-43. 7. Kumar L. Chronic myelogenous leukemia (CML): An update. Natl Med J India. 2006;19(5):255-63. 8. Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Reyling M, on behalf of the ESMO guidelines working group. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2012;23(Suppl 7):72-7. 9. Nguyen V, Rini BI. Chronic myelogenous leukemia. In: Bown CK, Rini BI, Connell PP, editors. Ontario: BD Decker Inc; 2005. p.532–45. 10. Paquette R, Hiller E, Munker R. The myeloproliferative syndromes. Contemporary hematology: Modern hematology: Biology and clinical management, 2nd Ed. New jersey: Humana press inc Totowa; 2007. p.137-54. 11. Lim TH, Tien SL, Lim P, Lim AST. The incidence and patterns of BCR-ABL rearrangements in chronic myeloid leukemia (CML) using fluorescence in situ hybridisation (FISH). Ann Acad Med Singapore. 2005;34(9):533-8. 12. Matti BF, Naji AS, Alwan AF. Evaluation of the safety of imatinib mesylate in 200 Iraqi patients with chronic myeloid leukemia in the chronic phase: single centre study. Turk J Haematol. 2013;30(4):387-93. 13. Tashfeen S, Ahmed S, Bhatti FA, Ali N. Real time polymerase chain reaction in diagnosis of chronic myeloid leukemia. J Coll Physicians Surg Pak. 2014;24(3);190-3. 14. Hernandez JM, Canizo MC, Garcia JL, Gutierrez NC, Gonzalez M, Castoldi G, et al. Clinical, hematological and cytogenetic characteristic of atypical chronis myeloid leukemia. Ann Oncol. 2000;11(4):441-4.

Recommended Citation

Rajabto, Wulyo; Harryanto, A.; Tadjoedin, Hilman; and Harimurti, Kuntjoro (2018) "Association of Clinical Features and Hematological Laboratoriesbetween Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia," Jurnal Penyakit Dalam Indonesia: Vol. 5: Iss. 1, Article 3.
DOI: 10.7454/jpdi.v5i1.167
Available at: https://scholarhub.ui.ac.id/jpdi/vol5/iss1/3